Tejada Cifuentes, FranciscoLloret Callejo, ÁngelesTirado Peláez, María JoséRubio Pulido, OlgaRuiz-Morote Aragón, MartaFernández Urrusuno, RocíoMuñoz Carreras, María IsabelMéndez Esteban, María IsabelMaestre Sánchez, VictoriaGarcía Bonilla, AntonioParedero Dominguez, José ManuelArroyo Pineda, VirginiaMarco Tejón, EstherRomero Candel, GregorioFernández Marchante, Ana IsabelMarco Del Rio, JoséOrtiz Martín, TeresaLópez Sánchez, Piedad2023-02-092023-02-092020-11-06http://hdl.handle.net/10668/16780To analyze the incidence of Covid-19 in patients who are chronic users of hydroxychloroquine. Cross-sectional retrospective observational multicenter study in health areas and districts from Castilla La-Mancha and Andalucia. Of the 4451 participants included in the first recruitment, 3817 with valid data were selected. The main variable of the study is the presence or absence of Covid-19 infection by clinical, serological or polymerase chain reaction diagnosis. Sociodemographic and clinical variables and treatment and concomitant comorbidities were recorded. 169 (4,45%) patients had Covid-19 infection, of which 12 (7.1%) died and 32 (18.9%) required hospital admission. Previous respiratory pathology was related to Covid-19 infection (P There is no relationship between chronic use of hydroxychloroquine and the incidence of Covid-19.enCOVID-19CoronavirusHidroxicloroquinaHydroxychloroquineIncidenceIncidenciaTratamientoTreatmentAdultAgedAged, 80 and overAntirheumatic AgentsArthritis, RheumatoidCOVID-19COVID-19 TestingChronic DiseaseCross-Sectional StudiesFemaleHumansHydroxychloroquineIncidenceLupus Erythematosus, SystemicMaleMiddle AgedPrognosisProtective FactorsRetrospective StudiesRisk FactorsSpainresearch article33308853open access10.1016/j.medcli.2020.10.0061578-8989PMC7833866https://doi.org/10.1016/j.medcli.2020.10.006https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833866/pdf